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Abstract
Background: Duchenne muscular dystrophy (DMD) causes progressive muscle degeneration, cardiomyopathy and
respiratory failure in approximately 1/5,000 boys. Golden Retriever muscular dystrophy (GRMD) resembles DMD both
clinically and pathologically. Like DMD, GRMD exhibits remarkable phenotypic variation among affected dogs,
suggesting the influence of modifiers. Understanding the role(s) of genetic modifiers of GRMD may identify
genes and pathways that also modify phenotypes in DMD and reveal novel therapies. Therefore, our objective
in this study was to identify genetic modifiers that affect discrete GRMD phenotypes.
Results: We performed a linear mixed-model (LMM) analysis using 16 variably-affected dogs from our GRMD
colony (8 dystrophic, 8 non-dystrophic). All of these dogs were either full or half-siblings, and phenotyped for
19 objective, quantitative biomarkers at ages 6 and 12 months. Each biomarker was individually assessed.
Gene expression profiles of 59 possible candidate genes were generated for two muscle types: the cranial
tibialis and medial head of the gastrocnemius. SNPs significantly associated with GRMD biomarkers were
identified on multiple chromosomes (including the X chromosome). Gene expression levels for candidate
genes located near these SNPs correlated with biomarker values, suggesting possible roles as GRMD modifiers.
Conclusions: The results of this study enhance our understanding of GRMD pathology and represent a first
step toward the characterization of GRMD modifiers that may be relevant to DMD pathology. Such modifiers
are likely to be useful for DMD treatment development based on their relationships to GRMD phenotypes.
Keywords: Muscular dystrophy, Duchenne muscular dystrophy, DMD, Golden retriever muscular dystrophy,
GRMD, Modifier, Linear mixed-model analysis, Gene expression
Background
Duchenne muscular dystrophy (DMD) is an X-linked
disease that causes progressive muscle degeneration in
approximately 1 out of 5,000 boys [1]. Skeletal and car-
diac muscle can both be affected, and, while the disease
is lethal, clinical presentations of DMD vary from patient
to patient (e.g. age at diagnosis, age at loss of ambula-
tion, body mass index, and lifespan [2, 3]). DMD pa-
tients are often wheelchair-bound by age 13 [4] and
typically succumb to cardiomyopathy and/or respiratory
complications before age 30. The primary molecular
cause of DMD is the absence of functional dystrophin, a
protein required for proper muscle function. Mutations
in the dystrophin gene, DMD [5], have been catalogued
extensively in humans (e.g. [2, 6–8]) and it is apparent
that the level of functional dystrophin is a key factor in
determining the severity of disease. In-frame mutations
resulting in truncated protein products cause the less-
severe Becker muscular dystrophy, while mutations
disrupting the reading frame cause the more-severe
DMD [9]. However, this “reading-frame rule” does
not always apply: cases have been documented of
children without any detectable dystrophin production
who display phenotypes so mild that clinical diagnosis
is ambiguous [10, 11].
Canine models for human diseases offer perspectives
not provided by smaller animal models. Dogs are more
physically comparable in size to humans than are mice;
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canine orthologs are available for approximately 92 % of
human genes [12]. The breeding structure used to
propagate many dog breeds supports breed-specific
stretches of genetic homogeneity, making the task of
identifying contributing genes more facile in dogs as
causal alleles segregate on a relatively homogeneous
background. Colonies of dogs have been invaluable for
understanding human conditions and developing treat-
ments (for example, Alport syndrome [13]; vaccine re-
sponse [14]); careful record-keeping and cooperation by
dog owners, veterinarians and researchers can also benefit
disease research [15].
Dog models for DMD have phenotypes that are very
similar to the human condition, making them powerful
for developing and testing new treatments. Preclinical
studies from dogs can predict the potential success of a
treatment in humans, as dog models of DMD are genet-
ically and phenotypically comparable to the human
disease [16] and, compared to mice, dogs are similar to
humans in body and organ size and immune response
[17]. Golden retriever muscular dystrophy (GRMD) is
the most extensively studied of the canine models of
dystrophin-deficient muscular dystrophy. GRMD is
remarkably similar to DMD both clinically and patho-
logically [18, 19]. Like DMD, dogs with GRMD are
afflicted with a progressive, fatal disease with limb skeletal
muscle, cardiac and respiratory involvement [20].
While DMD can be caused by many different types of
mutations in humans, GRMD is caused by a single
splice-site mutation that results in a frame shift and pre-
maturely truncated, nonfunctional protein product [21].
GRMD carrier females can be artificially inseminated by
GRMD-affected males to produce GRMD-affected fe-
males, which do not differ phenotypically from males;
affected females (aside from a few rare “manifesting car-
riers” [22, 23]) have not been seen in humans.
As a first step toward characterizing genetic modifiers
of GRMD, we performed a pilot study using linear
mixed-model (LMM) analysis of 8 variably-affected
dystrophic dogs and 8 non-dystrophic dogs, all either
full or half-siblings, with complete data available for age-
specific phenotypic measurements. We have also com-
pared our LMM findings with a cohort of unrelated dogs
to evaluate the GRMD population relative to a broader
population. GRMD disease grows progressively worse
with age and marked variation in disease severity is
observed between different muscles [20, 24], which sug-
gests that genetic modifiers of GRMD disease act differ-
entially between muscles. We have therefore included
two different age groups and two muscle types (the
cranial tibialis – a flexor, and the medial head of the
gastrocnemius – an extensor) in our analysis to evaluate
how gene expression changes with each variable. These
dogs were extensively phenotyped using biomarkers that
correlate with disease severity on multiple levels (for
example, force generated by different muscle groups).
These LMM analyses provide a foundation for future re-
search, including fine-mapping of phenotype-associated
modifier loci, targeted sequencing, and proteomics.
Methods
Animals
All GRMD dogs used in this study were from the col-
ony at the University of North Carolina at Chapel
Hill, now located at Texas A&M University. The dogs
were maintained and treated according to the stan-
dards of the National Research Council Guide for the
Care and Use of Laboratory Animals. Blood creatine
kinase levels taken shortly after birth were used to
diagnose neonates with GRMD [19], along with PCR
as previously described [25]. The colony is primarily
maintained by mating hemizygous GRMD males to
carrier females to produce approximately equal num-
bers of affected males and females.
Sixteen dogs were selected for this study based on the
availability of phenotypic data. This cohort included 8
GRMD-affected and 8 unaffected dogs from two age
groups: ~6 months (n = 9) and ~12 months (n = 7) of
age. The 6-month-old group contained 4 normal (all
male) and 5 affected (1 female and 4 males); the 12-
month-old group contained 4 normal (all male) and 3
affected (2 females and 1 male). These 16 dogs repre-
sented 5 litters; 13 of the dogs were half-sibs and the
remaining 3 were cousins to the other dogs. Three of
the 5 litters included both normal and affected dogs.
Also included in our study were the 7 unique parents
to the 16 phenotyped dogs. These parents were not
phenotyped, but were included to allow us to evaluate
linkage. A pedigree of the dogs is presented in Fig. 1.
Genotype data was also obtained for 19 unrelated and
unaffected golden retrievers for which muscle tissue
samples were not available.
Necropsies
Samples of muscle tissue were collected from the medial
head of the gastrocnemius and cranial tibialis at nec-
ropsy, flash-frozen in liquid nitrogen, and subsequently
stored at −80 °C.
Biomarker measurements
The phenotypes/biomarkers evaluated in this study were
developed for use in preclinical trials in GRMD dogs,
and are objective and quantitative. Detailed descriptions
of each biomarker and the method(s) of measurement
have been published previously [20, 24, 26–32] and
include: body-mass-corrected tibiotarsal joint (TTJ) tetanic
flexion and extension force (Newtons/kg; [24]), tibiotarsal
joint angle (degrees; [28]), eccentric contraction decrement
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(ECD) at 10 and 30 stimulations (percent; [29, 30]),
maximum hip flexion angle (degrees; [28]), pelvic angle
(degrees; [28]), body-mass-corrected cranial sartorius cir-
cumference (mm/kg; [20]), quadriceps femoris weight (g)
and quadriceps femoris weight corrected for body weight
(g/kg) [20], body weight (in kg) measurements taken at
1 month, 6 months, and 12 months of age [24], and ra-
tios of body weight to birth weight for each time point
(percent) [24].
The biomarkers used for this study provide objective
indices of disease severity. Because pathologic data were
collected at necropsy, we were able to assess terminal
muscle weights to gain further insight on the degree of
atrophy or hypertrophy. As an example, absolute and
body-mass-corrected weight of the quadriceps femoris,
the principal muscle involved in stifle (knee) extension
was assessed. Other biomarkers assessed functional pa-
rameters relevant to specific muscles used for validation
of candidate genes. Most notably, the cranial tibialis and
gastrocnemius are the principal muscles contributing to
TTJ tetanic flexion and extension, respectively. Tibiotar-
sal joint, maximum hip flexion, and pelvic joint angle
measurements provided objective insight on the severity
of debilitating contractures and postural instability in
GRMD and served as surrogates for overall muscle
imbalance and weakness that ultimately cause loss of
ambulation in severely affected dogs [33].
DNA extraction
DNA was extracted from tissue sections using the
phenol-chloroform-isoamyl alcohol method [34], as
modified by D. Ish-Horowitz [35].
Genotyping
DNA samples from the 16 GRMD affected and control
dogs, along with the 7 parental samples, were genotyped
on the Illumina CanineHD BeadChip (Illumina Inc, San
Diego, CA) and scored at GeneSeek (Lincoln, NE). Fur-
thermore, DNAs from 19 golden retrievers, unrelated to
the colony as well as to one another, were genotyped on
the same array to increase confidence in our results and
to evaluate the GRMD population relative to a broader
population, as described below.
Association studies
Linear mixed-model (LMM) analyses were performed
using three different methods to reduce the number of
false associations identified, and to overcome biases in-
herent to each methodology. Data from all dogs were
assessed by all three algorithms, which perform linear
mixed models based on clustering to account for both
population substructure and relatedness via a kinship
matrix estimated from identical by descent distances.
Associations between SNPs and biomarkers were ini-
tially identified using the whole genome association
Fig. 1 Pedigree representing the ancestry of the 16 dogs used in this study. Circles represent females; squares represent males; open symbols
represent non-GRMD (non-dystrophic); blackened symbols represent GRMD (dystrophic); a small circle within a larger circle represents GRMD carrier
females; animals listed in more than one position within the pedigree are indicated by a larger circle or square encompassing the primary symbol for
the animal, along with a dotted line connecting the multiple positions for that animal in the pedigree. The 16 dogs investigated for this study are listed
across the bottom of the pedigree, with names printed in bold green font
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analysis program plink [36]. Each biomarker was assessed
separately as its own endophenotype. SNPs were filtered
and pruned to reduce spurious associations. Inclusion
thresholds were 10 % maximum per-SNP missing, 5 %
maximum per-dog missing, and 10 % minimum minor al-
lele frequency (MAF). After applying these filters, 125,665
SNPs remained for analysis on all 16 dogs. Population
stratification was estimated for each endophenotype using
the genomic control λ value calculated by plink; a λ value
of 1 indicates no stratification, meaning association results
are not likely to be influenced by population structure
[37]. For plink results, adjustment for multiple testing
was done by using Bonferroni procedure with p-value
cutoff of 3.98 × 10−7 (=0.05/125665) to give pgenome-wide
< 0.05.) We subsequently performed association studies
using Genome-wide efficient mixed-model association
(GEMMA) [38] and SNP and Variation Suite (SVS)
(version 8.1.1) software to confirm the robustness of as-
sociations, similar to strategies used in previous studies
[39–41]. The linear mixed-model analysis GEMMA
allowed us to eliminate false associations due to breed-
ing structure. We performed three association tests: the
Wald test, likelihood ratio test, and score test, as de-
scribed in the GEMMA manual [42]. We furthermore
used the Efficient Mixed-Model Association (EMMA)
approach in SVS with the EMMAX (EMMA eXpedited)
technique for normalizing the kinship matrix [43, 44].
Results were further analyzed using R software [45] to
develop manhattan plots to visualize associations. Be-
cause the GRMD population used in this study consists
of related individuals, we used multidimensional scaling
(MDS) via plink to identify sample clustering and popu-
lation stratification with and without the unrelated
population of 19 golden retrievers.
The causal mutation responsible for GRMD has been
previously identified in the DMD gene [21] (located on
the canine X chromosome, positioned between bases
26290903–28444623; canine genome assembly version
3.1, Sept. 2011). Association with SNPs residing near or
within the DMD, using case–control analyses, con-
firmed the causal relationship between GRMD and the
DMD gene.
SNP effect prediction
All SNPs found to be statistically-significant via LMM
analysis were evaluated to determine possible effects of
SNPs on genes, transcripts, and protein sequences using
Ensembl’s Variant Effect Predictor [46].
Haplotyping and linkage disequilibrium
Since contributing loci are likely to be co-inherited
with significantly-associated SNPs, we developed hap-
lotypes using plink software [36] for those chromo-
somes containing significantly associated SNPs. Blocks
of linkage disequilibrium (LD) were then visualized with
Haploview [47].
Candidate modifier gene identification
Chromosomes and regions of LD found to harbor SNPs
statistically associated with one or more biomarkers
were manually examined to identify candidate genes.
We used the BioMart tool from the Ensembl genome
browser to extract information about positions and
functions of genes within regions of interest in the
canine genome, together with information about human
orthologs, where available. At the same time, we searched
the NCBI database for gene information, including associ-
ated phenotypes. Both databases provided information
about gene ontologies and interactions, providing add-
itional evidence to support possible roles for candidate
genes modifying GRMD phenotypes. Relevant publica-
tions, listed in the Bibliography section of the gene refer-
ence pages on NCBI, and Gene References into Function
(GeneRIFs) were also used to identify potential candidate
genes. Genes were selected for qPCR analysis if their
known or predicted function(s) were consistent with the
pathogenesis of muscular dystrophy (such as roles in
skeletal muscle or cardiac function), or if they interacted
with other gene(s) or pathway(s) relevant to the GRMD
phenotypes being studied.
RNA extraction
Total RNA was extracted from necropsy samples from
the cranial tibialis and medial head of the gastrocnemius
muscles archived at −80 °C for each of the 16 dogs using
TriPure Isolation Reagent (Roche; Indianapolis, IN) as
per manufacturer’s instructions. RNA was precipitated
using isopropanol and 75 % EtOH, and dissolved in
ultra-pure water. To minimize DNA contamination,
samples were DNase-treated using the DNA-Free DNase
Treatment and Removal kit (Ambion). The RNA con-
centrations in the individual samples were measured
using a Nanodrop 2000 spectrophotometer and assessed
for quality on a 2100 Bioanalyzer (Agilent Technologies,
Santa Clara, CA). The RIN values ranged from 7.5 – 8.2,
with the exception of one sample which had a RIN value
of 6.7. The Standards read 9.
Quantitative PCR (qPCR)
Total RNA was directly reverse transcribed to cDNA
using SuperScript II (Invitrogen). Briefly, samples of
skeletal muscle DNase-treated RNA (100 ng) were re-
verse transcribed with oligo-dT and random primers and
Superscript II (Invitrogen, Carlsbad, CA). The reverse
transcription reactions consisted of 100 ng of DNase-
treated RNA in a 50 μl reaction, ultra pure water, oligo
dT (2.5 μl of 500 ng/μl) and random hexamer (0.48 μl of
1 mM stock) heated to 65 °C for 5 min and cooled to
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room temperature. Next, Superscript II (2 μl), 5X 1st
Strand buffer (10 μl), 0.1 M DTT (5 μl), 10 mM dNTPs
(2.5 μl) and an RNase block Ambion’s Superasin (1 μl)
were added to the mix. All were heated to 37 °C for one
hour followed by reverse transcription inactivation at
90 °C for 5 min.
TaqMan® Gene Expression assays (Life Technologies,
Grand Island, NY; [48, 49]) were used to measure ex-
pression levels for 51 genes identified within candidate
gene regions. qPCR using TaqMan assays was performed
using MicroAmp Fast Optical 96 well plates (Applied
Biosystems). The qPCR reactions for each TaqMan assay
consisted of 10 μl TaqMan Gene Expression Master Mix,
1 μl TaqMan assay, 8.5 μl PCR grade water, and 0.5 μl of
each reverse transcription reaction (cDNA) for a total of
20 μl per well. TaqMan assays were not available for an
additional 8 genes; for these, we used SYBR Green tech-
nology to determine expression levels. Primers for genes
assessed via SYBR Green were designed from two neigh-
boring exons flanking one intron (when possible), or from
a single exon, using Primer3 software (http://biotools.
umassmed.edu/bioapps/primer3_www.cgi; [50]). Each
20 μl reaction contained 10 μl Power SYBR Green PCR
Master Mix (Applied Biosystems), 2 μl each forward and
reverse primers (3 μM each), 5.5 μl ultra-pure water, and
0.5 μl (1 ng) cDNA for a total of 20 μl per well. All qPCR
reactions were performed in duplicate using the 7900HT
Fast qPCR System (Applied Biosystems); primer and assay
information is listed in Additional file 1: Table S1. The
cycling parameters on the 7900HT machine were 50 °C
for 2 min, 95 °C for 10 min, and cycling 40 repeats of
95 °C for 15 s and 60 °C for 1 min. The parameters
were the same for the Sybr assays with a dissociation
curve added to validate primers.
No single housekeeping gene could be identified as
having steady expression levels across both muscle types
and age groups interrogated; therefore we used the geo-
metric mean strategy for data normalization, in which
the normalization factor is calculated using multiple
genes, as described [51]. Differential gene expression
was statistically evaluated via unpaired t-test using
GraphPad QuickCalcs Web site: http://graphpad.com/
quickcalcs/ttest1.cfm (accessed July 2014 [52]). Expres-
sion levels were considered significant at p < 0.05.
Linear regression correlating gene expression with clinical
phenotype measurements
Simple linear regression analyses between specific GRMD
quantitative phenotypes and expression values obtained
for each GRMD-affected dog were performed for each
of the 39 potential candidate genes identified by the
LMM analyses. All phenotype-transcript regression





Case/control association using plink confirmed the causal
mutation on Canis familiaris chromosome X CFAX, with
a genomic inflation factor λ = 1.
LMM analyses for other biomarkers in GRMD dogs,
performed using plink, resulted in different genomic infla-
tion factors (λ) (Table 1). λ values larger than 1.05 indicate
confounders such as population-level stratification or
family structure [39]; in this study, strong familial
structure is the likely culprit for some of the high λ
values. However, several biomarkers (shaded in Table 1)
were found to be relatively robust against stratification.
These biomarkers, therefore, appear to be the most reli-
able indicators of GRMD disease severity independent
of family structure.
Population stratification
MDS plots were constructed to visualize population
stratification, which could influence the relevance of var-
iants identified as significant. No stratification was ob-
served in the GRMD and parental samples. When the 19
unrelated golden retriever samples were added to the
total population and the results plotted, the unrelated
samples clustered tightly together, with GRMD samples
dispersed around on all sides of the unrelated sample
cluster (Fig. 2). This distribution reflects the nature of
Table 1 Genomic inflation factors calculated for GRMD biomarkers.
The biomarkers that are the most robust against stratification
are shaded
λ Biomarker
1.26 TTJ Tetanic flexion (N/kg)
1 TTJ Tetanic extension (N/kg)
1 TJA (degrees)
1.01 Percent eccentric contraction decrement (at 10 stimulations)
1 Percent eccentric contraction decrement (at 30 stimulations)
1 Maximum hip flexion angle
1 Pelvic angle
1.14 Cranial sartorius circumference (mm/kg)
1.23 Quadriceps femoris weight (g)
1.05 Quadriceps femoris weight (g/kg body weight)
1.38 Body weight at birth (kg)
1.53 Body weight at age 1 month (kg)
1.99 Percent body weight gain: birth-1 month
1 Body weight at age 6 months (kg)
1 Percent body weight gain: birth-6 months
1.22 Body weight (kg) at age 12 months
1.5 Percent body weight gain: birth-12 months
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the breeding strategy used for this GRMD colony, and
the resulting genetic diversity, which reduces population
stratification. Unrelated animals are added to the breed-
ing stock once the cumulative inbreeding coefficient of
the colony reaches ~0.20 (the point at which neonatal
mortality reaches 22 %) [31]. As a result, the GRMD col-
ony possesses many of the advantages of an inbred
population (e.g. reduced influence of confounding fac-
tors such as environmental variation), while capturing
genetic diversity more similar to that found in human
populations. In summary, the significant associations
discovered using the GRMD population are likely applic-
able to other populations as well.
Significant associations
We found 99 SNPs to be significantly associated with
GRMD phenotypic variation (FDR p <0.05). Following
Bonferroni correction, 7 of these SNPs also met signifi-
cance criteria (pBonferroni < 0.05) and 2 more showed a sug-
gestive association (pBonferroni < 0.1). These 9 SNPs were
located on 4 chromosomes in regions near or within genes
with functions relevant to GRMD phenotype, including
CFA7, 9, 23, and X (listed in Table 2; base pair [bp] posi-
tions given are from assembly version 3.1 of the canine
genome, known as CanFam3.1). Findings from analyses
using GEMMA and SVS concurred with the plink results,
adding credibility to the robustness of SNP associations
found with plink. Results from all SNP association experi-
ments are available in Additional file 2: Table S2.
SNP effects
SNPs from the associated regions on CFA7, 9, 23, and X
were evaluated for potential consequences using the
Ensembl Variant Effect Predictor tool [46]. No SNPs
were found to affect amino acid sequences, or alter
codons. Furthermore, no co-located variations were
found. The Variant Effect Predictor output is provided in
Additional file 3: Table S3.
Haplotypes
We evaluated LD and identified haplotype blocks for
CFA7, 9, 23, and X. Closely-located candidate modifier
genes within regions of strong LD may be inherited with
significant SNPs; therefore, we initially focused our gene
search on the regions surrounding significant SNPs. For ex-
ample, see Fig. 3, which shows a region on CFA9 that con-
tains SNPs in LD with each other and with SNPs within
the RAPGEF1 gene. However, due to the relatively outbred
nature of the GRMD colony and resulting lack of LD, we
did not limit our focus to the regions surrounding these
SNPs. Instead, we next expanded our candidate gene search
to regions beyond the immediate vicinity of phenotypically-
associated SNPs, as described in the next section.
Fig. 2 Multi-dimensional scaling (MDS) plots showing the genomic kinship between GRMD and unrelated golden retriever dogs, based on a set
of 125,665 SNPs (filtered based on inclusion parameters as described in Methods section). These graphs illustrate the distributions of two different
sets of coordinates across both populations. The unrelated dogs tended to cluster together near the center of the plots, while GRMD dogs appeared
as genetically more distant from each other
Table 2 Nine SNPs were most strongly associated with GRMD
biomarkers following Bonferroni correction. The first column lists
canine chromosome number and second column lists base-pair
location of the SNP (based on CanFam3.1). The third column
gives the SNP identifier
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Candidate gene identification
Regions of CFA 7, 9, 23, and X share synteny with re-
gions of the human genome which harbor loci encoding
proteins with functions relevant to DMD/GRMD.
CFA7
SNPs were identified in a ~19 Mb region of CFA7,
which shares homology with HSA18. In both species,
this region comprises a number of genes encoding pro-
teins involved in muscle and/or cardiovascular function.
For example, several of these proteins are associated
with dystrophin/muscle (dystrobrevin alpha - DTNA;
laminins alpha and gamma - LAMA1 and LAMC1;
lamin a – LMNA; and myomesin 1 – MYOM1). Others
are associated with cardiomyopathy, such as that ob-
served in DMD and GRMD (desmocollin 2 – DSC2;
desmoglein 2 – DSG2). We therefore investigated 11
candidate genes in this section of the dog genome.
CFA9
A 2 Mb region on CFA9 was associated with TTJ tetanic
flexion measurements. This section of CFA9 is homolo-
gous to segments of HSA15 and HSA9. Unlike CFA7,
this region is not home to many genes with obvious
potential roles in GRMD. We investigated one gene,
RAPGEF1, located on CFA9, which we identified as the
most likely to play a role in GRMD of the few genes in
this region.
Fig. 3 Association between tetanic flexion and loci on CFA9. In panel A, a Manhattan plot spotlights 16 significant SNPs (p < 0.01) associated with
tetanic flexion (in green), which suggest a relationship between this biomarker and one or more loci on CFA9. These SNPs are clustered between
bases 51735859–53937266 on CFA9; this region is illustrated in panel B. Panel C shows LD within this specific region in the GRMD dogs evaluated
in this study. The 16 significant SNPs are again spotlighted here, with green rectangles around the SNP names. Gene RAPGEF1 is located within a
region that is in LD with several of these significant SNPs; qPCR results confirmed that the expression of this gene in the cranial tibialis is associated
with tetanic flexion
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CFA23
The significant SNP associations found on CFA23 spot-
lighted two regions: a ~3 Mb region associated with ECD
at 30 stimulations, and a single SNP near the 12.8 Mb
position of the chromosome, associated with percent body
weight gain from birth to one month of age. Much of
CFA23 shares homology with HSA3; we evaluated 3
candidate genes from this chromosome for expression
differences in our GRMD cohort.
CFAX
We measured transcripts for three different sections of
DMD, and for additional loci on CFAX based on the lo-
cations of associated SNPs. In total, we evaluated expres-
sion levels for 7 loci on CFAX.
Genes outside of the regions of initial interest were
also considered for validation because of their biological
relevance.
CFA18
CFA18, homologous to HSA11, was not quite as strongly
correlated with GRMD biomarkers – in fact, the 2 SNPs
on CFA18 identified in this study were found to be only
nearly significant (FDR p-value = 0.06) and were associ-
ated with percent body weight gain from birth to one
month of age. However, the chromosome contains sev-
eral genes encoding proteins with functions pertaining
to skeletal muscle phenotypes or neuromuscular junc-
tion development; therefore, we investigated the expres-
sion levels of 16 genes from CFA18.
Other chromosomes
We investigated the transcript levels of 20 more genes
from chromosomes that were not found to harbor
significantly-associated SNPs. Several of these genes
were evaluated as potential “housekeeping” genes for
normalization (including ACTB, GUSB, PPIA, and
PSMD2), and most were not found to be suitable for
this role because they showed variable expression
levels across dogs. However, we chose to continue to
investigate some of these genes as potential candidate
modifiers based on their functions in related conditions
(for example, GUSB; see below). Others of this group of
genes encode proteins that have been suggested as modi-
fiers in DMD or mdx, and/or are involved in muscle re-
generation and degeneration, or were strongly associated
in follow-up LMM analyses by GEMMA or SVS (e.g.,
telomerase reverse transcriptase,TERT).
In total, we investigated 58 transcripts for differential
expression in GRMD and normal dogs. Gene names,
genomic positions and qPCR primer information for
these transcripts are listed in Additional file 1: Table S1.
Correlations between gene expression levels and
phenotypic measurements
We used qPCR to measure the expression of candidate
“modifier genes” in the cranial tibialis and medial head
of the gastrocnemius muscles of the same dogs used for
the mixed-model study. Relative expression data were
calculated using the ΔΔCt method of Livak and Schmittgen
[53], and normalized to the geomean. Of the original set of
58 genes, 12 were dropped from further analysis due to in-
consistent measurements across replicates. In total, we
measured the expression levels of 46 gene transcripts.
Fold-change comparisons are shown in Fig. 4 for all
genes.
Linear regression correlating gene expression with clinical
phenotype measurements
Linear regression analysis showed that expression levels of
some genes correlate directly with biomarker measurement
values (Fig. 5). This approach has been used successfully to
identify candidate modifiers in other studies in humans
and animals [54–58]. These findings increase confidence in
the relevance of potential candidate modifier genes. Obser-
vations made via linear regression offer novel avenues to
explore in future studies of the mechanisms underlying
specific GRMD – and DMD – phenotypes.
What is most interesting about the correlations found
via linear regression is the specificity of muscle type ob-
served in these relationships: correlations found between
transcript levels in the medial head of the gastrocnemius
vs those seen in the cranial tibialis. These results reflect
the differences in muscle injury in GRMD, further sug-
gesting that future treatment regimens could be tailored
to muscle type for maximum effectiveness. Here, all cor-
relations described involve 6-month-old dystrophic dogs
(n = 5). There were only 3 dystrophic 12-month-old
dogs, making linear regression analysis less powerful for
this age group; therefore we do not discuss here the
analysis for this cohort.
In the cranial tibialis muscle, transcripts from the
DMD2 primer set, located near exons 7–8 of the DMD
gene, were decreased with greater tetanic flexion values.
It is unclear whether any of this transcript was translated
into a protein; the transcript was likely subject to
nonsense-mediated decay and therefore it is difficult to
make a true connection between this biomarker and
DMD2 levels. We found that decreasing levels of desmo-
glein 2 (DSG2) transcript within the cranial tibialis muscle
were correlated with increasing measurement values for
tetanic flexion. DSG2 encodes a calcium-binding trans-
membrane glycoprotein which has been implicated in
right ventricular cardiomyopathy [59]. While cardiomyop-
athy is indeed a part of GRMD disease, here we observed
transcriptional activity within skeletal muscle. Next, lam-
inin, alpha 1 (LAMA1) transcript levels decreased in the
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cranial tibialis in tandem with increasing quadriceps
femoris weight (when corrected for body weight) at age
6 months. LAMA1 encodes the laminin a1 chain of the
laminin-111 heterotrimer, a protein previously investi-
gated for therapeutic potential in mdx mice [60]. Add-
itionally, low density lipoprotein receptor-related
protein 4 (LRP4) is involved with the maintenance of
neuromuscular synapse formation and neuromuscular
junction [61]. We associated higher levels of LRP4
transcript in the cranial tibialis with larger tetanic ex-
tension measurements. Finally, transcript levels of a
gene called peptidase domain containing associated
with muscle regeneration 1 (PAMR1) in the cranial
tibialis associated linearly with eccentric contraction
decrement at 10 stimulations as well as quadriceps
femoris weight when corrected for body weight. In
both instances, increases in the amount of PAMR1
transcript were correlated with increases in measure-
ment values of these biomarkers. Overall, the cranial
tibialis muscle showed the most linearity between
transcript levels of candidate modifier genes and bio-
marker measurement values.
The medial head of the gastrocnemius muscle is
affected differently than the cranial tibialis. Not surpris-
ingly, transcript levels of different candidate genes were
associated with GRMD biomarkers. In another example
of linear correlation, beta glucuronidase (GUSB) expres-
sion levels in the medial head of the gastrocnemius of 6-
month-old GRMD dogs decreased with increased tetanic
extension measurements (R2 = 0.81), which also suggest
a relationship between transcript levels of these genes
and GRMD phenotype. Also in the medial head of the
gastrocnemius of 6-month-old GRMD dogs, transcript
levels of laminin, beta 1 (LAMB1) correlated nearly per-
fectly with measurements of quadriceps femoris weight
(R2 = 0.83 for muscle weights themselves, and R2 = 0.98
when overall body weight was also taken into consider-
ation). In other words, increased weight of the quadri-
ceps femoris was associated with decreased levels of
LAMB1. Furthermore, LAMB1 expression correlated
Fig. 4 Gene expression levels following normalization against a normal (non-dystrophic) dog and geometric mean [53]. * = significantly different
between GRMD and non-dystrophic dogs (unpaired t test; p < 0.05). ** = very significantly different between GRMD and non-dystrophic dogs
(unpaired t test; p < 0.01). + = near significant (unpaired t test; p < 0.06)
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well with eccentric contraction decrement measure-
ments after 10 stimulations. LAMB1 is one of several
extracellular matrix glycoproteins and has been previ-
ously associated with muscular dystrophies – particu-
larly limb-girdle muscular dystrophy, where LAMB1
levels have been observed to be decreased [62].
Comparisons of expression at different ages
In the cranial tibilalis of 6-month-old dogs, expression
was significantly different between GRMD and normal
dogs for 11 genes; for 12-month-old dogs, a significant
difference was seen for 12 genes (including 6 of the same
genes that were differentially expressed at age 6 months).
In the medial head of the gastrocnemius, we found 4
genes to have significantly different expression levels be-
tween GRMD and normal dogs at age 6 months. 3 of
these remained significant in comparisons at 12 months
of age, along with 5 additional genes.
Comparisons of expression in different muscles and at
different ages
While the cranial tibialis and medial head of the gastro-
cnemius are both located in the distal pelvic limb, their
functions differ. The cranial tibialis is a flexor of the
tibiotarsal joint, while the medial head of the gastrocne-
mius is an extensor. Natural history functional data
Fig. 5 Linear regression analyses performed on the 5 affected 6-month-old GRMD dogs are shown for those genes whose transcript levels (x-axis)
correlated with phenotypic measurement values (y-axis). Each plot shows the linear regression equation and correlation coefficient (R2). Results
are not shown for 12-month-old GRMD dogs because there were only 3 affected dogs in that group. CT = cranial tibialis, MHG =medial head of
the gastrocnemius, ECD = eccentric contraction deficiency (at 10 or 30 stimulations), quad fem wt g = quadriceps femoris weight in grams
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indicate that TTJ flexors are affected relatively early in
the disease course and recover to some extent [24]. On
the other hand, TTJ extensors are affected later in the
disease course. Similarly, the medial head of the gastro-
cnemius undergoes considerably greater atrophy than
the cranial tibialis [20].
The two muscles we evaluated have different (often
opposite) functions in GRMD clinical signs, and expres-
sion level comparisons between affected and unaffected
dogs were found to be significant in both muscles for
only the DMD gene, as expected. DMD2 was significant
in both age groups in the cranial tibialis and at 6 months
in the medial head of the gastrocnemius, while differen-
tial expression of DMD3 was significant at both ages in
the cranial tibialis.
Overall, more genes were differentially-expressed in
the cranial tibialis than the gastrocnemius. This could be
due to the fact that the cranial tibialis is affected earlier
in the course of GRMD disease. Some of these
differentially-expressed genes had statistically-significant
expression differences specifically in one muscle but not
the other, an observation which could have implications
for the different ways these muscles function in GRMD.
Beta glucuronidase (GUSB) was originally selected as a
possible housekeeping gene for normalization, but sur-
prisingly we found the expression of GUSB to vary
substantially. We observed that GUSB expression
levels were increased in the cranial tibialis in GRMD
relative to normal dogs at both ages, while levels in the
gastrocnemius were fairly equal. Likewise, laminin
gamma 1 (LAMC1), peptidase domain containing asso-
ciated with muscle regeneration 1 (PAMR1) and pepti-
dylprolyl isomerase A (PPIA) expression differences
were significant only in the cranial tibialis. However,
these differences were significant in both 6- and 12-
month-old age groups.
Similarly, 3 genes showed significant differential ex-
pression only in the medial head of the gastrocnemius.
These included lipase, member H (LIPH), phospho-
diesterase 8B (PDE8B) and slit guidance ligand 2
(SLIT2). Each of these genes was found to have signifi-
cant differences in expression level between dystrophic
and non-dystrophic dogs at both ages.
We observed age-specific differential expression for
FXR1 (fragile X mental retardation, autosomal homo-
log 1) and thrombospondin 4 (THBS4). Both of these
genes showed the greatest differences in expression
level at 12 months of age. This could reflect the in-
creased severity of GRMD disease at 12 months com-
pared to 6 months of age, or it could highlight a
specific phase of development during which these
genes are most active. The protein encoded by FXR1
plays a role in myogenesis [63], while THBS4 is involved
in nervous system development.
Transcription of the DMD gene
We found measurable transcript levels of the DMD gene
in the 8 dystrophic GRMD dogs. These levels varied
based on the locations of the primers within DMD, and
muscle type. Paradoxically, in both the cranial tibialis
and gastrocnemius, transcript levels were higher in
GRMD versus non-dystrophic dogs for all three sections
of the DMD gene. However, in both muscle types, tran-
script levels were not the same for all three segments
of DMD.
Statistically-significant up-regulation of DMD tran-
scripts was found in the cranial tibialis at age 6 months
in dystrophic versus non-dystrophic dogs. By age
12 months, however, only transcripts representing some
of the 5’ part of the gene (known here as DMD2, with
primers designed across exons 7–8) were found to be
significantly increased, both for the cranial tibialis and
the medial head of the gastrocnemius. While it is not
surprising to find evidence of transcription upstream of
the causal GRMD mutation, the findings for primers
DMD1 and DMD3 were unexpected. These assays repre-
sent sections of the DMD gene that are farther down-
stream (exons 46–47 and 69–70, respectively), yet
measurable transcription was observed in the cranial
tibialis of 6-month-old dogs. Moreover, these transcripts
were significantly up-regulated in GRMD dogs when
compared with non-dystrophic dogs.
DMD transcripts have been previously identified in the
cranial sartorius and vastus lateralis muscles of dys-
trophic dogs [64] as well as in dystrophic mice [65];
however, these transcripts were more often found to be
from the 5’ end of the gene sequence than the 3’end.
This imbalance was postulated to explain the observed
transcription of DMD in these studies, an explanation
that may apply to some of our own findings from the
cranial tibialis. These and other studies also suggest that
these rogue DMD transcripts are likely to be subject to
nonsense mediated decay and completely nonfunctional
at the protein level [65–67]. However, our lab has found
evidence of protein expression (M. Schneck, personal
communication) which suggests that translation of these
DMD transcripts takes place to some extent.
Previous studies have postulated that exon-skipping
can occur in human DMD, in cases where a causal point
mutation either disrupts enhancer sequences or creates
suppressor sequences leading to atypical exon splicing
[68, 69]. Such situations could instigate exon skipping,
resulting in variable levels of dystrophin production
[70–75]. Mutations within certain regions of DMD tend
to be more prone to this type of phenomena, which may
explain some of the phenotypic variation in DMD [69]:
alternate start codons or alternate splicing in the 5’
(proximal) end of the DMD gene can “rescue” the dys-
trophin transcript [4, 76–78]. This region includes
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intron 7, which is highly susceptible to mutation in
humans [79, 80]. Importantly, this region is also hom-
ologous to that of the GRMD causal mutation [81].
Therefore, it is possible that DMD transcription and
translation in GRMD dogs can be explained by exon-
skipping; we intend to investigate this theory via sequen-
cing and additional protein studies.
Discussion
The clinical variability seen in DMD suggests that
disease outcome is influenced by genetic modifiers of
the causal mutation in the DMD gene. Genetic modifiers
that influence phenotypes can serve as additional drug-
gable targets for treatment. In humans, the search for
genetic modifiers is confounded by the large number of
mutations associated with DMD and the absence of de-
fined genetic populations. Animal models of the disease
are useful for discovery of genetic modifiers because the
genetic backgrounds are relatively homogeneous, par-
ticularly for the causal DMD mutation. However, the use
of models that do not resemble the human disease may
limit the relevancy of modifiers discovered.
The GRMD colony at Texas A&M University is fairly
inbred yet sufficiently genetically diverse to study com-
plex phenotypes such as those observed in DMD. All
GRMD dogs are descended from the same founding sire
and all share a common causal mutation, but variation is
observable in the progression of disease and severity of
the phenotype [32]. The breeding strategy employed is
such that the Texas A&M GRMD colony possesses
many of the advantages of an inbred population (e.g. re-
duced influence of confounding factors such as environ-
mental variation), but unlike inbred mice, GRMD dogs
feature genetic diversity more similar to that found in
human populations. The identification of genetic modi-
fiers is therefore simplified by using our GRMD colony
and requires a smaller sample size than would a study
using humans [82]. Understanding the role(s) of genetic
modifiers of GRMD may identify genes and pathways
that also modify phenotypes in DMD and reveal novel
therapies.
This study represents a preliminary characterization
of the GRMD model to identify potential candidate
modifier genes. The extensive LD found in many dog
breeds allows the efficient identification of causal gen-
etic variants for Mendelian conditions. However, find-
ing modifier genes for more complex phenotypes is
less straightforward. Populations where heterozygosity
is more prevalent than seen in typical inbred popula-
tions add to the challenge, but can provide results
that are arguably more relevant to a broader popula-
tion. The analyses described here are meant to serve
as a pilot study for evaluating the likelihood of gen-
etic modifiers of GRMD phenotypes. We anticipate
that our findings will provide a starting point for add-
itional studies.
In this paper we have presented evidence for genetic
influences on objective phenotypic biomarkers in GRMD.
Our study allowed us to compare mildly and severely
affected GRMD dogs with high degrees of relatedness
without confounding factors such as environmental
differences. We used a sample set that included GRMD
affected dogs of both genders, but as in previous studies
we did not see any significant gender-specific difference in
biomarker measurements. With our small cohort of dogs,
we identified regions that correlated with GRMD bio-
markers in some way, perhaps directly or as a part of a
larger pathway. It should be noted that the applicability of
the results we describe here are limited to the GRMD
model, though the putative candidate genes we have iden-
tified provide support for future investigations toward the
identification and characterization of modifier genes.
Because of the high degree of similarity between GRMD
and DMD, such searches are of utmost importance to ex-
pand and enhance the relevance and applicability of this
animal model for understanding the “minor players”
(called “secondary effects” versus “primary” effects of dys-
trophin deficiency; [83]) of DMD disease variation (e.g.,
the underlying genetic background affecting variant DMD
phenotypes) and for developing novel therapeutics (e.g.,
trials for drugs and other experimental therapies). While
the power of this particular study is limited by the small
number of subjects, our results indicate that GRMD phe-
notypes are, indeed, susceptible to genetic background.
The fact that qPCR values for the same genes differed
between muscles suggests that pathways or mechanisms
vary for individual muscles. As expected, there was also
differential expression with age, reflecting the stage of
disease. While this is not surprising, the implications
must be considered when evaluating the outcomes of
clinical trials. It may be that targeted treatments will be
a preferable option for some patients for whom other
therapies (e.g. stem cell, gene replacement, or chemical)
have failed to produce satisfactory results. In these situa-
tions, understanding the involvement of specific sets of
genes on different muscles or time points could lead to
treatments that, for example, improve one aspect of
DMD disease without detrimentally affecting others.
Conclusions
For monogenic conditions such as DMD that show a
spectrum of phenotypes, there is tremendous value in
identifying potential modifiers. Such modifiers could in-
fluence outcomes of therapeutic trials performed using
GRMD as a model for DMD. On the other hand, modi-
fiers may also serve as targets for novel therapeutics.
Detecting these genes, therefore, facilitates the role that
the GRMD model plays in accelerating DMD treatment
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development. Characterization of genomic variation
underlying GRMD phenotypic variation will present a
powerful resource for understanding the molecular causes
behind variable DMD phenotypes.
Additional files
Additional file 1: Table S1. Primer and assay information for qPCR
experiments. The Gene IDs and associated Gene Names are found on the
left, followed by their CFA chromosomal locations (chromosome number),
and start and end positions (in bp) based on CanFam3.2. The TaqMan
assays or SybrGreen primer sequences used for qPCR are presented next,
along with the associated UniGene ID (where available). The remaining
columns indicate which mRNA and protein sequences are associated with
the investigated genes, along with the locations of the qPCR assays
themselves and size of the expected amplicon. (XLSX 34 kb)
Additional file 2: Table S2. (located at http://dog.genomezoo.net/) SNP
associations, listed by chromosomal location, are group by association
method (e.g. plink, GEMMA, and SVS). For all associations, phenotypes are
given in the leftmost column, followed by information about the SNP/marker
and its location, allele frequencies, and statistical information.
Additional file 3: Table S3. Variant Effect Predictor output for 90 SNPs
found to be significantly associated with phenotypes. The legend for the
table is located at the bottom of the table, along with the count numbers
for each of the different variants found by Ensembl’s Variant Effect Predictor.
Rows for different SNPs and the genes they affect are colored differently,
and the font of the gene names are formatted differently, to indicate the
muscle types (if any) in which that gene was investigated. (XLSX 35 kb)
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